Results 91 to 100 of about 820 (140)

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Journal of Blood Medicine, 2021
Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia ...
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD   +9 more
doaj  

Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests

Romanian Journal of Laboratory Medicine
This study presents a transversal investigation that we performed at Fundeni hospital (Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A.
Brinza Melen, Uscatescu Valentina, Hemcinschi Mihai, Chiriac Elisabeta, Gherghe Georgiana, Coriu Daniel   +5 more
doaj   +1 more source

Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis

São Paulo Medical Journal
BACKGROUND: Until recently, the treatment of people with hemophilia A and inhibitors (PwHAi) was based on the use of bypassing agents (BPA). However, the advent of emicizumab as prophylaxis has demonstrated promising results.
Tiago Paiva Prudente, Ricardo Mesquita Camelo, Rafael Alves Guimarães, Maria do Rosário Ferraz Roberti   +3 more
doaj   +1 more source

HINODE study: haemophilia A in infancy and newborns – protocol for a prospective, multicentre, observational study evaluating the coagulation potential and safety of emicizumab prophylaxis

BMJ Open
Introduction Emicizumab prophylaxis is approved for people of all ages with haemophilia A (HA) including infants and children. Although previous studies have demonstrated the efficacy and tolerability of emicizumab in infants with HA, real-world data on ...
Shouichi Ohga, Hirosuke Inoue, Keiji Nogami, Masahiro Takeyama, Masataka Ishimura, Daisuke Nosaka, Keisuke Iwasaki, Chika Mitsui   +7 more
doaj   +1 more source

PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience

Bleeding, Thrombosis and Vascular Biology
Background and Aims: Hemophilia A (HA) is an hereditary X-linked bleeding disorder secondary to deficiency of the clotting factor VIII (FVIII), that, if not properly treated, is associated with debilitating joint damage due to recurrent hemarthroses as ...
doaj   +1 more source

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Drug Design, Development and Therapy, 2020
Sandra Le Quellec1,2 1Unité d’hémostase Clinique – Hôpital Cardiologique Louis Pradel – Hospices Civils de Lyon, Lyon, France; 2Service d’hématologie biologique, Groupement Hospitalier Est &ndash ...
Le Quellec S
doaj  

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays

Research and Practice in Thrombosis and Haemostasis
Background: Denecimig (Mim8, Novo Nordisk A/S) is a next-generation bispecific antibody designed to mimic activated factor (F)VIII and restore hemostasis in persons with hemophilia A.
Jacob Lund, Mirella Ezban, Kasper Jensen, David Lillicrap   +3 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Real-World Impact of Emicizumab and Immunosuppression on Acquired Hemophilia A: A Multicenter Us Cohort

Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST).
von Drygalski, Annette, Al Banaa, Kadhim, Escobar, Miguel A, Ellsworth, Patrick, Malec, Lynn M, Zhou, Jenny Y, Wu, James F, Kruse-Jarres, Rebecca, Chen, Evan C, Kessler, Craig M, Cafuir, Lorraine, Bryan, Cassandra, Poston, Jacqueline N, Parnes, Aric, Walsh, Christopher, Khan, Osman, Janbain, Maissaa   +16 more
core   +1 more source